VIEW WEBSITE >>

1 known investors

Mironid develops drug therapies targeting cAMP degrading phosphodiesterase enzymes for autosomal dominant polycystic kidney disease and other rare kidney diseases with significant unmet medical needs.

BiotechHealthtechMedical Devices